Anti-GPRC5D/anti-CD3 bispecific T-cell engager therapy(Integral Molecular)

N/A

Report date: 2024/05/14 17:36:32

Base Information

Drug NameAnti-GPRC5D/anti-CD3 bispecific T-cell engager therapy(Integral Molecular)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionG-protein coupled receptor family C group 5member D modulatorsT cell surface glycoprotein CD3 modulators
TargetsG-protein coupled receptor family C group 5member DT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A